Here's What Raymond James Says About Spyre Therapeutics Inc (SYRE) [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
a press release that it raised around $463.5 million in gross proceeds from its recent equity offering. The company offered 7.48 million shares of its common stock, and granted the underwriters the option to purchase an additional 975,000 shares. The underwriters fully exercised their option. The shares were offered at a price of $62 apiece, near the 52-week high. Here's What Raymond James Says About Spyre Therapeutics Inc (SYRE) Looker_Studio/Shutterstock.com Notably, Spyre's equity raise adds to a solid cash position. At the end of 2025, Spyre had $757 million of cash, cash equivalents, and marketable securities. The company estimated that this cash would be enough to fund its operations into the second half of 2028. On April 13, Raymond James launched coverage of Spyre Therapeutics Inc (NASDAQ:SYRE) stock with a Strong Buy rating and a price target of $80. The firm pointed to the potential of Spyre's clinical programs for its bullish view on the stock. Spyre is developing
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SYRE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- Spyre Therapeutics (SYRE) had its price target raised by JonesTrading from $64.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionGlobeNewswire
- Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data [Yahoo! Finance]Yahoo! Finance
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 4/22/26 - Form SCHEDULE
- 4/20/26 - Form SCHEDULE
- 4/16/26 - Form 8-K
- SYRE's page on the SEC website